Kwon Hye-Young, Kim Hyungmin, Godman Brian, Reich Michael R
a 1 Department of Global Health and Population, Harvard School of Public Health, Boston, MA 02115, USA.
b 2 Institute of Health and Environment, Graduate School of Public Health, Seoul National University, Seoul, South Korea.
Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):1007-14. doi: 10.1586/14737167.2015.1083425. Epub 2015 Sep 22.
A new pricing policy was introduced in Korea in April 2012 with the aim of strengthening competition among off-patent drugs by eliminating price gaps between originators and generics.
Examine the effect of newly implemented pricing policy.
Retrospectively examining the effects through extracting from the National Health Insurance claims data a 30-month panel dataset (January 2011-June 2013) containing consumption data in four major therapeutic classes (antihypertensives, lipid-lowering drugs, antiulcerants and antidepressants). Proxies for market competition were examined before and after the policy.
The new pricing policy did not enhance competition among off-patent drugs. In fact, price dispersion significantly decreased as opposed to the expected change. Originator-to-generic utilization increased 6.12 times (p = 0.000) after the new policy.
The new pricing policy made no impact on competition among off-patent drugs. Competition in the off-patent market cannot be enhanced unless both supply and demand side measures are coordinated.
2012年4月韩国出台了一项新的定价政策，旨在通过消除原研药和仿制药之间的价格差距来加强非专利药之间的竞争。
研究新实施的定价政策的效果。
通过从国家健康保险理赔数据中提取一个包含四个主要治疗类别（抗高血压药、降脂药、抗溃疡药和抗抑郁药）消费数据的30个月面板数据集（2011年1月至2013年6月），回顾性地研究其效果。在政策实施前后对市场竞争的代理指标进行了考察。
新的定价政策并未增强非专利药之间的竞争。事实上，与预期变化相反，价格离散度显著降低。新政策实施后，原研药与仿制药的使用量增长了6.12倍（p = 0.000）。
新的定价政策对非专利药之间的竞争没有影响。除非供需双方的措施得到协调，否则非专利药市场的竞争无法得到加强。
Zotero 插件